Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
To answer the first question, we measured malondialdehyde (MDA) level the product of the brain aldehydic lipid peroxidation and 8-epi Prostaglandin F2 (8-epi PGF2) concentration a marker of oxidative stress and antioxidant deficiency
Published trials are sparse, but a 2023 observational study reported modest additional weight loss (35 lbs over 12 weeks) with combination therapy versus single-agent, though nausea and dizziness occurred in 34% of patients
Instead, I recommend saving your money and focusing on proven methods for addressing back pain
You must visit the emergency room if you experience chest pain
in such taxable years generally may elect to accelerate and deduct the remaining unamortized amounts of such research and development expenses (i) in the first taxable year beginning after December 31, 2024, or (ii) ratably over the two-taxable year period beginning with the first taxable year beginning after December 31, 2024
